Tissue penetration of antimicrobials: Difference between revisions

From IDWiki
Line 13: Line 13:
 
| rowspan="3" |[[Penicillins]]
 
| rowspan="3" |[[Penicillins]]
 
|Ξ²-lactamase inhibitors
 
|Ξ²-lactamase inhibitors
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
|-
 
|-
 
|[[ampicillin]]
 
|[[ampicillin]]
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" |–
 
| style="text-align:center" |–
 
|-
 
|-
 
|[[piperacillin-tazobactam]]
 
|[[piperacillin-tazobactam]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" | +†
βˆ’
| +†
 
  +
| style="text-align:center" |
βˆ’
|
 
 
|-
 
|-
 
| rowspan="5" |[[Cephalosporins]]
 
| rowspan="5" |[[Cephalosporins]]
 
|first-generation cephalosporins
 
|first-generation cephalosporins
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" |–
 
| style="text-align:center" |–
 
|-
 
|-
 
|second-generation cephalosporins
 
|second-generation cephalosporins
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
|-
 
|-
 
|third-generation cephalosporins
 
|third-generation cephalosporins
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" | +†
βˆ’
| +†
 
  +
| style="text-align:center" |
βˆ’
|
 
 
|-
 
|-
 
|[[cefepime]]
 
|[[cefepime]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
|-
 
|-
 
|[[ceftazidime]]
 
|[[ceftazidime]]
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
|-
 
|-
 
| rowspan="2" |[[Cephamycins]]
 
| rowspan="2" |[[Cephamycins]]
 
|[[cephamycins]]
 
|[[cephamycins]]
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
|-
 
|-
 
|[[cefoxitin]]
 
|[[cefoxitin]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" |–
 
| style="text-align:center" |–
 
|-
 
|-
 
|[[Carbapenems]]
 
|[[Carbapenems]]
 
|[[imipenem]]
 
|[[imipenem]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
|-
 
|-
Line 95: Line 95:
 
|-
 
|-
 
|[[Aminoglycosides]]
 
|[[Aminoglycosides]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" |–
 
| style="text-align:center" |–
 
|-
 
|-
 
|[[Chloramphenicol]]
 
|[[Chloramphenicol]]
 
|[[chloramphenicol]]
 
|[[chloramphenicol]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
|-
 
|-
 
|[[Fluoroquinolones]]
 
|[[Fluoroquinolones]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" |–?
 
| style="text-align:center" |–?
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
| style="text-align:center" | +
Line 120: Line 120:
 
|[[Fosfomycin]]
 
|[[Fosfomycin]]
 
|[[fosfomycin]]
 
|[[fosfomycin]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" | +
βˆ’
| +
 
  +
| style="text-align:center" |
βˆ’
|
 
 
|-
 
|-
 
|[[Lincosamides]]
 
|[[Lincosamides]]
 
|[[clindamycin]]
 
|[[clindamycin]]
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
|-
 
|-
 
|[[Macrolides]]
 
|[[Macrolides]]
 
|[[macrolides]]
 
|[[macrolides]]
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
  +
| style="text-align:center" |
βˆ’
|
 
 
|-
 
|-
 
|[[Nitrofurans]]
 
|[[Nitrofurans]]
Line 152: Line 152:
 
|[[Nitroimidazoles]]
 
|[[Nitroimidazoles]]
 
|[[metronidazole]]
 
|[[metronidazole]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
|-
 
|-
 
|[[Rifamycins]]
 
|[[Rifamycins]]
 
|[[rifampin]]
 
|[[rifampin]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
  +
| style="text-align:center" |
βˆ’
|
 
 
|-
 
|-
 
|[[Sulfonamides]]
 
|[[Sulfonamides]]
 
|[[trimethoprim-sulfamethoxazole]]
 
|[[trimethoprim-sulfamethoxazole]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
  +
| style="text-align:center" |
βˆ’
|
 
 
|-
 
|-
 
| rowspan="2" |[[Tetracyclines]]
 
| rowspan="2" |[[Tetracyclines]]
 
|[[tetracyclines]]
 
|[[tetracyclines]]
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
  +
| style="text-align:center" |
βˆ’
|
 
 
|-
 
|-
 
|[[doxycycline]]
 
|[[doxycycline]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" | +
βˆ’
| +
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
|-
 
|-
Line 193: Line 193:
 
|[[Azoles]]
 
|[[Azoles]]
 
|[[fluconazole]]
 
|[[fluconazole]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
|-
 
|-
 
|[[Echinocandins]]
 
|[[Echinocandins]]
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" | +
βˆ’
| +
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |–
βˆ’
|–
 
  +
| style="text-align:center" |
βˆ’
|
 
  +
| style="text-align:center" |
βˆ’
|
 
 
|-
 
|-
 
!Class
 
!Class

Revision as of 14:50, 16 September 2020

Summary

Class Antimicrobial Blood CNS Urine Prostate Necrotic
Antibiotics: Ξ²-Lactams
Penicillins Ξ²-lactamase inhibitors –
ampicillin + –
piperacillin-tazobactam +†
Cephalosporins first-generation cephalosporins – –
second-generation cephalosporins –
third-generation cephalosporins +†
cefepime +
ceftazidime + +
Cephamycins cephamycins –
cefoxitin –
Carbapenems imipenem +
Antibiotics: Non-Ξ²-Lactams
Aminoglycosides –
Chloramphenicol chloramphenicol +
Fluoroquinolones –? + +
Fosfomycin fosfomycin +
Lincosamides clindamycin – +
Macrolides macrolides – +
Nitrofurans nitrofurantoin – – + – –
Nitroimidazoles metronidazole +
Rifamycins rifampin +
Sulfonamides trimethoprim-sulfamethoxazole +
Tetracyclines tetracyclines – +
doxycycline + +
Antifungals
Azoles fluconazole +
Echinocandins + –
Class Antimicrobial Blood CNS Urine Prostate Necrotic
  • † if inflammation present

Prostate

  • Poorly penetrated by most antibiotics
  • Penetration is higher with a high concentration gradient, high lipid solubility, low degree of ionization, high dissociation constant, low protein binding, and small molecular size
  • Fluoroquinolones are the mainstay of therapy, though there is increasing resistance
  • TMP-SMX often used, though conflicting data about its penetration into the prostate
  • Minocycline, doxycycline, and macrolides achieve high levels in the prostate but are rarely indicated for the causative organisms
  • Third-generation cephalosporins and carbapenems can be used
  • Piperacillin, aztreonam, imipenem, and some aminoglycosides are likely useful

References

  1. ^  Cornelia B. Landersdorfer, JΓΌrgen B. Bulitta, Martina Kinzig, Ulrike Holzgrabe, Fritz SΓΆrgel. Penetration of Antibacterials into Bone. Clinical Pharmacokinetics. 2009;48(2):89-124. doi:10.2165/00003088-200948020-00002.
  2. a b c d e f g h i j k l m n o p q r  L. Brockhaus, D. Goldblum, L. Eggenschwiler, S. Zimmerli, C. Marzolini. Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics. Clinical Microbiology and Infection. 2019;25(11):1364-1369. doi:10.1016/j.cmi.2019.01.017.
  3. a b  Takashi Suzuki, Toshihiko Uno, Guangming Chen, Yuichi Ohashi. Ocular distribution of intravenously administered micafungin in rabbits. Journal of Infection and Chemotherapy. 2008;14(3):204-207. doi:10.1007/s10156-008-0612-5.
  4. a b c d e f g h  T. Felton, P. F. Troke, W. W. Hope. Tissue Penetration of Antifungal Agents. Clinical Microbiology Reviews. 2014;27(1):68-88. doi:10.1128/cmr.00046-13.